

List of Figure

Fig. 2.1	Formulation approaches to improve oral bioavailability	22
Fig. 2.2	Intestinal pre-absorptive processes	25
Fig. 2.3	Fate of SEDDS and SMEDDS following oral administration and mechanisms proposed for bioavailability enhancement of drug	26
Fig. 2.4	Overview of Anatomy of Nasal cavity	31
Fig. 2.5	Mechanism of nasal Transport of Drug Molecule	34
Fig. 2.6	Bicontinuous structure of Microemulsion system	38
Fig. 2.7	Pseudo ternary phase diagram of oil, water and surfactant	39
Fig. 2.8	A Modified Balance, B Weights, C Glass Vial, E, F Membrane, G Height Adjustable Pan	42
Fig. 3.1	Presumable Mechanisms of Action of Vinpocetine	60
Fig. 4.1	Calibration Plot of Modafinil in ACN:Water (35:65) by UV Spectroscopy	79
Fig. 4.2	First Order Derivative of Modafinil by UV Spectroscopy	80
Fig. 4.3	Calibration plot of Modafinil in ACN:Water (35:65) by UV spectroscopy	80
Fig. 4.4	Excipients interference chart for Modafinil by UV visible Spectrophotometer	83
Fig. 4.5	Graphical Spectrum of Modafinil Calibration Plot by HPLC Method	83
Fig. 4.6	Calibration plot for Modafinil in Methanol: Water mobile phase by HPLC	84
Fig. 4.7	Excipients Interference chart of Modafinil by HPLC	87
Fig. 4.8	HPLC chromatogram of Modafinil in Plasma	87
Fig. 4.9	Calibration Plot of Modafinil by HPLC in Plasma	88
Fig. 4.10	Calibration Plot of Vinpocetine in Methanol by UV Spectroscopy	95
Fig. 4.11	Calibration Plot of Vinpocetine in Methanol at 314nm	96
Fig. 4.12	Excipients Interference chart of Vinpocetine by UV-visible Spectrophotometer	98
Fig. 4.13	Calibration plot of Vinpocetine in diffusion media at 314nm	99
Fig. 4.14	Calibration Plot for Vinpocetine by HPLC	100
Fig. 4.15	Graphical spectrum of Vinpocetine Calibration plot by HPLC method	102
Fig. 4.16	Calibration Plot for Vinpocetine by HPLC Method	103
Fig. 4.17	Calibration Plot of Vinpocetine in Plasma by HPLC	104

Fig. 4.18	Graphical spectrum of Vinpocetine Calibration plot in Plasma by HPLC method	105
Fig. 4.19	Calibration Plot of Vinpocetine in Plasma by HPLC	105
Fig. 4.20	Graphical spectrum of Vinpocetine Calibration plot in Brain Homogenate by HPLC method	106
Fig. 4.21	Calibration Plot of Vinpocetine in Brain Homogenate by HPLC	107
Fig. 5.1	FT-IR spectra of Modafinil drug	119
Fig. 5.2	DSC thermogram of Drug: Modafinil	120
Fig. 5.3	Solubility of Modafinil in Different Oils	122
Fig. 5.4	Solubility of Modafinil in Different Surfactants	123
Fig. 5.5	Solubility of Modafinil in Different Co-surfactants	124
Fig. 5.6	FT-IR Spectra of Blank SMEDDS	125
Fig. 5.7	FT-IR Spectra of Modafinil loaded SMEDDS	126
Fig. 5.8	Pseudo ternary Phase Diagram at Different Km Value	127
Fig. 5.9	Interaction effects of Oil, Surfactant and Co-surfactant on globule size using	133
Fig. 5.10	3D Surface plot: Interaction effects of Oil, Surfactant and Co-surfactant on globule size using 3D Surface plot	134
Fig. 5.11	Contour plot: Interaction effects of Oil, Surfactant and Co-surfactant on Percentage Transmittance	137
Fig. 5.12	3D Surface plot: Interaction effects of Oil, Surfactant and Co-surfactant on Percentage Transmittance	137
Fig. 5.13	Desirability Plot for Selection of Parameters	138
Fig. 5.14	Overlay Plot for SMEDDS	139
Fig. 5.15	Vinpocetine microemulsion and mucoadhesive microemulsion preparation	145
Fig. 5.16	FT-IR spectra of Vinpocetine	147
Fig. 5.17	DSC thermogram of Drug: Vinpocetine	148
Fig. 5.18	Solubility of Vinpocetine in different oils, surfactant and co-surfactant	150
Fig. 5.19	FT-IR spectra of Drug loaded mixture of Capmul MCM C8, Tween 80 and PEG-400	152
Fig. 5.20	Pseudo ternary Phase Diagram at different Km value	153

Fig. 5.21	Design with the three factors A, B and C	155
Fig. 5.22	Interaction effects of Oil, Aqueous phase and Smix on Globule size using 3D surface Plot: (A) as Oil decreases, size decreases, (B) as Aqueous phase decreases, size decreases, (C) as Smix increases, size decreases	159
Fig. 5.23	Response surface curve (3D plot) showing combined effect of independent variables on % Transmittance. (A) as Oil decreases, %T increases, (B) as Aqueous decreases, %T increases, (C) as Smix increases, %T increases	162
Fig. 5.24	Desirability Plot for selection of parameters	163
Fig. 5.25	Overlay plot for Microemulsion	165
Fig. 6.1	Globule size for 100 times diluted SMEDDS	177
Fig. 6.2	Zeta Potential for 100 times diluted SMEDDS	178
Fig. 6.3	TEM image of the diluted SMEDDS of Modafinil	180
Fig. 6.4	Globule size of Vinpocetine Loaded Microemulsion (ME)	187
Fig. 6.5	Globule size of Vinpocetine Loaded Mucoadhesive Microemulsion (MME)	187
Fig. 6.6	Zeta Potential of Vinpocetine Loaded Microemulsion (ME)	187
Fig. 6.7	Zeta Potential of Vinpocetine Loaded Mucoadhesive Microemulsion (MME)	188
Fig. 6.8	Histopathology study for evaluation of Nasal Toxicity (A) PBS pH 6.4, (B) IPA, (C) ME, and (D) MME.	190
Fig. 6.9	TEM image of the Mucoadhesive Microemulsion of Vinpocetine	191
Fig. 7.1	Dissolution profiles of SMEDDS, drug and marketed formulation	199
Fig. 7.2	Effect of pH on In vitro dissolution profiles of SMEDDS	200
Fig. 7.3	In vitro drug diffusion profiles of SMEDDS and drug	202
Fig. 7.4	Ex vivo drug diffusion profile of SMEDDS and drug from Stomach	203
Fig. 7.5	Ex vivo drug diffusion profile of SMEDDS and drug from Intestine	204
Fig. 7.6	Franz diffusion cell	207
Fig. 7.7	In vitro diffusion profile of Vinpocetine loaded ME, MME and Suspension	211
Fig. 7.8	Ex vivo drug release of Vinpocetine loaded ME, MME and Suspension	213
Fig. 8.1	Plasma drug concentration vs time profiles of Modafinil after oral administration of suspension, marketed product and SMEDDS	219

Fig. 8.2	Plasma drug concentration vs time profiles of Vinpocetine after Nasal administration of ME, MME and oral administration of Suspension.	225
Fig. 8.3	Brain drug concentration vs time profiles of Vinpocetine after Nasal administration of vinpocetine loaded ME, MME and oral administration of Suspension.	226
Fig. 9.1	Stability study of Modafinil loaded SMEDDS at Room Temperature	233
Fig. 9.2	Stability study of Modafinil loaded SMEDDS at Accelerated Conditions	233
Fig. 9.3	Stability study of ME at Room Temperature	238
Fig. 9.4	Stability study of ME at Accelerated Conditions	238
Fig. 9.5	Stability study of MME at Room Temperature	240
Fig. 9.6	Stability study of MME at Accelerated Conditions	240
Fig. 10.1	Learning and Intact Reference Memory	247
Fig. 10.2	Short Term Working Memory	248
Fig. 10.3	Percentage time spent in each quadrant on Day 6.	249
Fig. 10.4	Percentage time spent in each quadrant on Day 7.	250
Fig. 10.5	Percentage time spent in each quadrant on Day 8.	251
Fig. 10.6	Learning and Intact Reference Memory	253
Fig. 10.7	Short Term Working Memory	254
Fig. 10.8	Percentage time spent in each quadrant on Day 6.	255
Fig. 10.9	Percentage time spent in each quadrant on Day 7.	256
Fig. 10.10	Percentage time spent in each quadrant on Day 8.	257